BRIEF-Exelixis says phase 2 trial met primary endpoint for advanced renal cell carcinoma

* Announces results from randomized phase 2 trial cabosun demonstrate cabozantinib significantly improved progression free survival versus sunitinib in previously untreated advanced renal cell carcinoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)